Please assess the completion status of the following clinical trial:

Trial Title: Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who signed a personal consent to participate in the study,~* Patients with a typical clinical picture of moderately-severe to severe plaque psoriasis (PASI SCORE ≥10) and~* DMT2 diagnosed at least 6 months before inclusion in the study,~* Patients who were not treated with immunosuppressive therapy.~Exclusion Criteria:~* Other forms of psoriasis,~* Other chronic, inflammatory diseases (data obtained by reviewing the medical history),~* Drugs that can cause the appearance of psoriasis (lithium, systemic antimalarials, systemic corticosteroids) - for the past 3 months,~* Systemic therapy of vulgaris psoriasis 3 months before inclusion in the study,~* Patients on therapy with other GLP-1 RAs except semaglutide (liraglutide, dulaglutide, lixisenatide), SGLT-2 inhibitors (empagliflozin and dapagliflozin) and NSAIDs, photo UVB therapy,~* Patients who did not personally sign consent to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- semaglutide (Type: EXPERIMENTAL): The initial dose of the medicine is 0.25 mg once a week, for the duration of 4 weeks. Then the dose is increased to 0.5 mg per week, for the duration of 4 weeks. After at least 4 weeks, the dose can be increased from 0.5 mg to 1 mg per 4 week. Totally 12 weeks
- controled group (Type: NO_INTERVENTION): Patients with DMT2 and psoriasis, who are already on metformin therapy in the maximally tolerated dose and other oral antidiabetics, except on therapy with GLP-1 RA and SGLT-2 inhibitors.

Based on this trial design, predict the completion outcome and termination type (if applicable).